Big pharma in big China

While many are jumping on the China bandwagon for less expensive manufacturing and research and development, the country is also developing low-cost medicines that seriously undercut U.S. prices and might just transform the U.S. drug industry entirely. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.